Brolucizumab is under clinical development by Novartis and currently in Phase III for Polypoidal Choroidal Vasculopathy. According to GlobalData, Phase III drugs for Polypoidal Choroidal Vasculopathy does not have sufficient historical data to build an indication benchmark PTSR for Phase III. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Brolucizumab LoA Report. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Brolucizumab overview

Brolucizumab-dbll (Beovu, Vsiqq, Vizcu, Pagenax) is a recombinant human vascular endothelial growth factor. It is formulated as solution for intravitreal route of administration. Beovu is indicated for the treatment of neovascular (Wet) age-related macular degeneration. Beovu is indicated for the treatment of diabetic macular edema.

Brolucizumab (DLX-1008) is under development for proliferative diabetic retinopathy. It is administered topically and intravitreally. The therapeutic candidate targets VEGF-A and is developed based on the Pentra technology platform which utilizes Pentra antibody fragments. It was also under development for the treatment of keloids, rosacea, Kaposi's sarcoma, diabetic macular edema and glioblastoma.

It was under development for the treatment of visual impairment due to macular edema secondary to branch retinal vein occlusion, macular edema secondary to central retinal vein occlusion.

Novartis overview

Novartis is a healthcare company that focuses on the discovery, development, manufacture and marketing of prescription and generic pharmaceutical products and eye care products. It provides drugs for the treatment of cancer, cardiovascular diseases, dermatological conditions, neurological disorders, ophthalmic and respiratory diseases, hematologic diseases, solid tumors, immune disorders, and infections, among others. The company offers generic medicines and biosimilars through Sandoz. Novartis conducts research in various disease areas through The Novartis Institutes for BioMedical Research (NIBR). The company operates through a network of subsidiaries and offices across the Americas, Europe, the Middle East, Africa, and Asia-Pacific. Novartis is headquartered in Basel, Switzerland.

For a complete picture of Brolucizumab’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.